By Stephen Nakrosis
Vanda Pharmaceuticals said the Food and Drug Administration accepted the filing of the company’s new drug application for tradipitant to treat symptoms of gastroparesis.
Gastroparesis is characterized by delayed gastric emptying with symptoms including bloating, nausea, vomiting and abdominal pain, the company said Monday.
Vanda said about 6 million patients in the U.S. have gastroparesis, many of whom remain undiagnosed.
Write to Stephen Nakrosis at [email protected]
Read the full article here